ALNY Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.3B
+10.6%
1.2B
+6.4%
1.1B
-12.2%
1.2B
+61.4%
773.7M
Cost of Revenue
298.3M
+43.7%
207.5M
-22.5%
267.7M
+35.7%
197.2M
+38.9%
142.0M
Gross Profit
992.7M
+3.4%
959.7M
+15.7%
829.3M
-21.2%
1.1B
+66.5%
631.7M
Operating Expenses
761.2M
+10.2%
691.0M
-0.9%
697.6M
+2.0%
683.8M
+5.5%
647.9M
R&D
413.1M
+13.2%
364.9M
-2.0%
372.2M
+3.7%
358.8M
+10.9%
323.6M
SG&A
347.9M
+7.9%
322.6M
-0.9%
325.4M
+1.0%
322.1M
-0.4%
323.3M
Operating Income
231.4M
-13.8%
268.6M
+103.9%
131.7M
-64.2%
368.0M
+2371.6%
-16199000
EBITDA
245.3M
-13.1%
282.2M
+94.3%
145.2M
-62.0%
381.8M
+17030.6%
-2255000
Net Income
164.5M
-20.1%
206.0M
+10.5%
186.4M
-25.8%
251.1M
+447.6%
-72228000
EPS (Basic)
$1.23
-20.6%
$1.55
+9.9%
$1.41
-26.2%
$1.91
+447.3%
$-0.55
EPS (Diluted)
$1.21
-19.9%
$1.51
+14.4%
$1.32
-28.3%
$1.84
+434.5%
$-0.55
Shares (Diluted)
138.3M
+0.0%
138.2M
-2.0%
141.1M
+2.7%
137.3M
+5.1%
130.6M
Alnylam Pharmaceuticals (ALNY) โ€” Financials